Metformin reduces endogenous reactive oxygen species and associated DNA damage.

Abstract excerpt

Pharmacoepidemiologic studies provide evidence that use of metformin, a drug commonly prescribed for type II diabetes, is associated with a substantial reduction in cancer risk. Experimental models show that metformin inhibits the growth of certain neoplasms by cell autonomous mechanisms such as activation of AMP kinase with secondary inhibition of protein synthesis or by an indirect mechanism involving reduction...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Epidermal Growth Factor
• Share to Adenylate Kinase